Welcome to our dedicated page for Dr Reddys Labs news (Ticker: RDY), a resource for investors and traders seeking the latest updates and insights on Dr Reddys Labs stock.
Dr. Reddy's Laboratories Limited reports news on its global pharmaceutical business, including APIs, generics, branded generics, biosimilars and OTC medicines. Company updates cover product approvals and launches in regulated markets, such as generic semaglutide in Canada and OTC ophthalmic products in the U.S., as well as biosimilar development, regulatory submissions and strategic partnerships.
Recurring coverage also includes IFRS financial results, segment trends across Global Generics and Pharmaceutical Services and Active Ingredients, and market activity in the USA, India, Russia and CIS countries, China, Brazil and Europe. Related research releases include Aurigene Oncology updates on oncology programs and targeted protein degradation platforms.
Dr. Reddy’s Laboratories has acquired a portfolio of branded and generic injectable products from Eton Pharmaceuticals for approximately $5 million upfront, with potential contingent payments of $45 million. The acquisition includes the NDAs for Biorphen® and Rezipres® injections and aims to enhance Dr. Reddy’s institutional business in the U.S. market, where the total addressable market for these products is estimated at $174 million for the year ending April 2022. This move supports Dr. Reddy’s commitment to expanding affordable medications.
Dr. Reddy’s Laboratories Ltd. has launched Sorafenib Tablets, USP, a generic equivalent of Nexavar (sorafenib) in the U.S. market following approval from the U.S. Food and Drug Administration (USFDA). The 200 mg tablets are available in bottles of 120. CEO Marc Kikuchi emphasized the company's commitment to providing affordable medicines. This launch enhances Dr. Reddy's offerings in the oncology segment, expanding their portfolio aimed at improving patient access to critical treatments.
Dr. Reddy's Laboratories Ltd. has launched Pemetrexed for Injection in 100 mg and 500 mg single-dose vials, approved by the USFDA. This generic version is an equivalent to ALIMTA®, which generated approximately $1.24 billion in US sales for the twelve months ending March 2022. The introduction of this generic product expands Dr. Reddy's offerings in oncology and positions the company in a significant market segment, potentially benefiting its financial growth.
Dr. Reddy's Laboratories and Senores Pharmaceuticals announced the launch of Ketorolac Tromethamine Tablets USP, 10 mg in the U.S., a generic equivalent of Toradol. This nonsteroidal anti-inflammatory drug (NSAID) is indicated for short-term management of acute pain. The U.S. market for Toradol tablets had sales of approximately $16.8 million in the past year. The product is available in bottles of 100, enhancing Dr. Reddy's portfolio in the U.S. market.
Dr. Reddy’s Laboratories has launched Posaconazole Delayed-Release Tablets, a generic equivalent to NOXAFIL®, approved by the U.S. FDA. The product is now available in 100 mg strength, with U.S. sales of NOXAFIL® reaching approximately $140.8 million over the past year. This move supports Dr. Reddy’s commitment to providing affordable, innovative medicines. The tablets come in a bottle count of 60.
Dr. Reddy’s Laboratories has launched Methylprednisolone Sodium Succinate for Injection, a generic version of SOLU-MEDROL® in the U.S., approved by the USFDA. The brand and its generic have recorded U.S. sales of approximately $144 million over the last twelve months ending February 2022, according to IQVIA Health. This product is available in both single-dose and multi-dose vials. Dr. Reddy’s focuses on providing affordable medicines and operates in major markets including the U.S., India, and Europe.
Dr. Reddy's (NYSE:RDY) has launched medical cannabis products in Germany through an exclusive distribution agreement with MediCane. This partnership, established in 2021, allows Dr. Reddy's to market MediCane's products while also co-funding a phase II clinical trial targeting Behavioral and Psychological Symptoms of Dementia (BPSD). With Germany's medical cannabis market growing, valued at ~122 million euros and expanding at a ~25% growth rate, this alliance positions Dr. Reddy's to significantly impact the European market, capitalizing on increasing patient demand.
Dr. Reddy's Laboratories Ltd. has launched its authorized generic version of VASOSTRICT® (vasopressin injection, USP) in the U.S. This release, approved by the U.S. Food and Drug Administration, responds to a significant market demand, with the VASOSTRICT® brand generating approximately $878.5 million in U.S. sales over the past twelve months ending December 2021.
The product is supplied in a carton of 25 single-dose vials, each containing vasopressin 1 mL at 20 units/mL. This launch is particularly relevant during the ongoing COVID-19 pandemic.
Dr. Reddy's Laboratories has announced its definitive agreement to acquire Nimbus Health GmbH, a licensed pharmaceutical wholesaler based in Germany, focusing on medical cannabis. This acquisition involves an upfront payment and performance-based earn-outs expected over the next four years. With a growing medical cannabis market in Germany, currently valued at ~€122 million and experiencing significant growth, this strategic move aims to leverage Nimbus Health's strengths in serving patients with unmet medical needs. The transaction is subject to customary closing conditions.
Summary not available.